Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsChristopher Viehbacher - President, CEO ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...

Monoclonal antibodies are a type of biologic medication that can treat moderate to severe inflammatory bowel disease (IBD) by targeting specific inflammatory processes in your body. Your doctor might ...

F10 Antiseptic Wound Spray with Insecticide received the EUA based on scientific evidence available. The FDA announced earlier this week it issued an Emergency Use Authorization (EUA) for benzalkonium ...

After more than 160 years, the AVMA welcomed its first Black president, marking a new chapter in the organization’s history. In 1863, 40 veterinary surgeons representing New York, Massachusetts, Maine ...

March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact media@fredhutch.org to schedule interviews. Scientists develop ...

EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...